MXCT: MaxCyte EV/EBITDA Multiple

Corporate emblem and logo of MaxCyte (MXCT)

The price trajectory of MaxCyte, Inc. (MXCT) demonstrates a correlation with revenues from the sale of cell gene modification systems, where the EV/EBITDA multiple stands at 0.00. Profits are based on the consistent sale of branded replacement modules for laboratories. Exchange rate stability is supported by confident management and transparent long-term contracts with biotech partners, which guarantee regular cash inflows.

MaxCyte Inc - MXCT Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for maxcyte.com (MXCT)

- stock price and consensus target price:
Stock Quotes MaxCyte, Inc|MXCT - Analyst Forecast Prices
- market capitalization information:
Market Capitalization MaxCyte Inc|MXCT - Company Buyout Price
- issuer book value statistics:
Book Value per Share MaxCyte|MXCT - Company Net Assets|Market Cap to Net Assets Ratio maxcyte.com|MXCT - Aggregate Asset Value
- company liabilities and liquidity data:
Debt to Equity MaxCyte, Inc.|MXCT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital MaxCyte|MXCT - Company Cumulative Debt|Debts to Book Capitalization MaxCyte Inc|MXCT - Company Long-Term Indebtedness|Company Short-Term Debts MaxCyte|Quick Ratio maxcyte.com
- financial results and valuation multiples details:
MXCT - Net Income|Projected Future Earnings MaxCyte, Inc.|MXCT - P/E Multiple|Future Price to Earnings MaxCyte, Inc.|MXCT - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio MaxCyte Inc|MXCT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) MaxCyte|MXCT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months maxcyte.com|MXCT - Net earnings per share change in current year|Expected earnings per share growth for next year MaxCyte, Inc.
Initial company analysis:MaxCyte, Inc MXCT
Original product of maxcyte.com

MaxCyte, Inc. (MXCT) is developing a scalable cell engineering platform where growth in consumables sales activates operating leverage. By analyzing the EV/EBITDA multiple trend, an investor assesses the business value relative to its operating profit before depreciation and amortization. This metric determines the company's resilience to rising costs and debt burdens during yield fluctuations. A decline in the ratio signals potential losses or a temporary downturn in fundamental value.

Competitor analysis for MaxCyte, Inc.

Abbott Laboratories Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TMO (Thermo Scientific)|GE HealthCare - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio mt.com MTD|WAT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bio-Techne Corp|Enterprise Value to EBITDA Ratio BRKR|AZTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Varex Imaging (VREX)|Enterprise Value to EBITDA Ratio semlerscientific.com SMLR|EV/EBITDA Multiple BFLY (Butterfly Network)|Mesa Laboratories Inc (MLAB) - Company Value to EBITDA|Quantum-Si Corp - EV/EBITDA Multiple|NNOX (Nano-X Imaging Ltd) - Enterprise Value to Operating Income Before Depreciation|QTRX: EV/EBITDA Multiple|MASS - Total Company Value to Operating Income Before Depreciation Ratio|CV (CapsoVision, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Rapid Micro (RPID)|EV/EBITDA Multiple SEER|EV/EBITDA Multiple Hyperfine Medical (HYPR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FONAR Corporation FONR|Daxor Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDAI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIVS (Organovo Holdings)|ACON: EV/EBITDA Multiple|Company Value to EBITDA Akoya Biosciences, Inc. (AKYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ThermoGenesis|TLIS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems)